Arax Advisory Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.57M | Buy |
68,126
+47,608
| +232% | +$2.52M | 0.02% | 599 |
|
|
2026
Q1 | $1.13M | Sell |
20,518
-5,523
| -21% | -$299K | 0.03% | 400 |
|
|
2025
Q4 | $1.28M | Sell |
26,041
-5,476
| -17% | -$255K | 0.04% | 329 |
|
|
2025
Q3 | $1.36M | Buy |
31,517
+11,764
| +60% | +$460K | 0.02% | 555 |
|
|
2025
Q2 | $759K | Buy |
19,753
+12,187
| +161% | +$466K | 0.03% | 301 |
|
|
2025
Q1 | $293K | Buy |
7,566
+6,152
| +435% | +$225K | 0.02% | 435 |
|
|
2024
Q4 | $47.8K | Buy |
1,414
+480
| +51% | +$17.3K | ﹤0.01% | 922 |
|
|
2024
Q3 | $38.2K | Sell |
934
-20
| -2% | -$818 | ﹤0.01% | 816 |
|
|
2024
Q2 | $36.7K | Sell |
954
-1,642
| -63% | -$69.1K | ﹤0.01% | 758 |
|
|
2024
Q1 | $111K | Buy |
2,596
+17
| +0.7% | +$701 | 0.01% | 374 |
|
|
2023
Q4 | $95.6K | Buy |
2,579
+101
| +4% | +$3.63K | 0.01% | 388 |
|
|
2023
Q3 | $89.8K | Buy |
2,478
+565
| +30% | +$20.1K | 0.01% | 367 |
|
|
2023
Q2 | $68.2K | Buy |
1,913
+823
| +76% | +$29.5K | 0.01% | 417 |
|
|
2023
Q1 | $38.8K | Buy |
1,090
+377
| +53% | +$13.2K | 0.01% | 495 |
|
|
2022
Q4 | $25.1K | Hold |
713
| – | – | ﹤0.01% | 535 |
|
|
2022
Q3 | $21K | Buy |
713
+38
| +6% | +$1.44K | ﹤0.01% | 562 |
|
|
2022
Q2 | $37K | Hold |
675
| – | – | 0.01% | 468 |
|
|
2022
Q1 | $37K | Sell |
675
-27
| -4% | -$1.47K | ﹤0.01% | 492 |
|
|
2021
Q4 | $39K | Buy |
702
+27
| +4% | +$1.41K | ﹤0.01% | 487 |
|
|
2021
Q3 | $32K | Buy |
675
+13
| +2% | +$653 | ﹤0.01% | 502 |
|
|
2021
Q2 | $33K | Buy |
+662
| New | +$31.8K | ﹤0.01% | 525 |
|
|
2020
Q4 | $30K | Hold |
662
| – | – | ﹤0.01% | 460 |
|
|
2020
Q3 | $31K | Hold |
662
| – | – | 0.01% | 434 |
|
|
2020
Q2 | $34K | Buy |
662
+182
| +38% | +$9.34K | 0.01% | 414 |
|
|
2020
Q1 | $23K | Hold |
480
| – | – | 0.01% | 442 |
|
|
2019
Q4 | $28K | Hold |
480
| – | – | 0.01% | 388 |
|
|
2019
Q3 | $26K | Hold |
480
| – | – | 0.01% | 392 |
|
|
2019
Q2 | $24K | Buy |
+480
| New | +$24.1K | 0.01% | 395 |
|
|
2018
Q4 | $27K | Sell |
563
-223
| -28% | -$11K | 0.01% | 341 |
|
|
2018
Q3 | $39K | Sell |
786
-1,605
| -67% | -$81.5K | 0.02% | 310 |
|
|
2018
Q2 | $120K | Buy |
2,391
+96
| +4% | +$4.83K | 0.05% | 139 |
|
|
2018
Q1 | $112K | Buy |
2,295
+885
| +63% | +$41.2K | 0.06% | 125 |
|
|
2017
Q4 | $62K | Buy |
1,410
+72
| +5% | +$3.33K | 0.03% | 194 |
|
|
2017
Q3 | $67K | Sell |
1,338
-152
| -10% | -$7.71K | 0.03% | 183 |
|
|
2017
Q2 | $76K | Buy |
1,490
+76
| +5% | +$4.05K | 0.04% | 180 |
|
|
2017
Q1 | $74K | Buy |
1,414
+3
| +0.2% | +$152 | 0.04% | 157 |
|
|
2016
Q4 | $68K | Buy |
+1,411
| New | +$69.7K | 0.03% | 140 |
|
Other funds holding GSK
JEST
Arax Advisory Partners's GSK Position: Q2 2026 in Review
Arax Advisory Partners increased its GSK (GSK) stake by 232% in Q2 2026, buying an estimated $2.52M and bringing the position to 68,126 shares worth $3.57M. The position accounts for 0.02% of the portfolio, ranked #599.
Arax Advisory Partners first reported a position in GSK in Q4 2016 and has held it in 37 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Arax Advisory Partners held 68,126 shares of GSK worth $3.57M as of Q2 2026.
- Arax Advisory Partners bought 47,608 GSK shares in Q2 2026, an estimated $2.52M.
- GSK made up 0.02% of Arax Advisory Partners's portfolio in Q2 2026, its #599 holding.
- Arax Advisory Partners first reported a position in GSK in Q4 2016 and has held it in 37 quarters since.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.